Organogenesis (NASDAQ:ORGO) Cut to Strong Sell at Wall Street Zen

Wall Street Zen cut shares of Organogenesis (NASDAQ:ORGO) from a sell rating to a strong sell rating in a research note published on Saturday.

Several other analysts have also commented on the stock. UBS Group set a $3.00 price target on shares of Organogenesis in a research report on Thursday, May 28th. Truist Financial lowered their price objective on Organogenesis from $3.00 to $2.00 and set a “hold” rating for the company in a research report on Friday. Weiss Ratings cut Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, BTIG Research downgraded Organogenesis from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Reduce” and an average target price of $4.33.

Organogenesis Price Performance

Organogenesis stock opened at $1.86 on Friday. The company has a current ratio of 3.52, a quick ratio of 3.00 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average price of $2.41 and a 200 day moving average price of $2.74. Organogenesis has a 12-month low of $1.54 and a 12-month high of $7.08. The stock has a market cap of $239.34 million, a P/E ratio of -2.16 and a beta of 1.34.

Organogenesis (NASDAQ:ORGO) last posted its earnings results on Thursday, August 6th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.36). Organogenesis had a negative net margin of 19.94% and a negative return on equity of 23.89%. The firm had revenue of $43.76 million during the quarter, compared to analyst estimates of $54.27 million.

Hedge Funds Weigh In On Organogenesis

Several large investors have recently made changes to their positions in the stock. Quarry LP purchased a new position in shares of Organogenesis during the 3rd quarter worth approximately $25,000. Flagship Harbor Advisors LLC purchased a new stake in Organogenesis in the fourth quarter valued at approximately $34,000. Pallas Capital Advisors LLC purchased a new stake in Organogenesis in the second quarter valued at approximately $37,000. Federated Hermes Inc. lifted its stake in Organogenesis by 52.8% during the fourth quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock worth $44,000 after purchasing an additional 2,953 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in Organogenesis during the second quarter worth $45,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.